Digital Health Technology Darmiyan’s BrainSee Receives FDA Approval for Post-Market Surveillance StudyMay 29, 2025 Darmiyan’s BrainSee, an AI-powered prognostic tool for Alzheimer’s disease, has received FDA approval for a 7-year post-market surveillance study to further validate its safety and effectiveness.
